Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) has lately been going through difficult times. The most tragic point was when the biopharma pronounced the failure of the drugs in the Phase II trial. These had been targeted towards the treatment of very severe lung cancer. The test confirmed that the drug did not meet the required endpoint, something […]
Spectrum Pharmaceuticals Inc
Recent Posts
AmpliTech Reports FY 2022 Results; Beats Revenue Guidance and Reports Record 267% YoY Annual Revenue Increase to $19.4 Million
Summary of Concussion
OMID Posts 2022 Annual Report and Provides Update
AmpliTech Records a New Benchmark at Satellite 2023 Show in Washington, D.C.
Premier Biomedical Inc. (OTC: BIEI), Welcomes Officers, Directors and Key Advisors
Popular Post
-
Sports Gambling and the Horse Racing Market
-
ZICIX+CTIP-FII RECEIVES NOTICE TO PROCEED FROM PROJECT OWNER TO START THE $20 MILLION SENIOR CITIZENS RESIDENCE PROJECT IN NEWARK, NEW JERSEY
-
Mass Megawatts Targets Solar Customers throughout the Northeast and its Solar Tracker’s Time of Use (TOU) Rates Advantages Become More Important When California’s NEM 3 Takes Effect Next Month
-
Principal Solar to Acquire Minerva-Rockdale Leases, Wells, and Assets
-
Kona Gold Beverage, Inc Announces its Ooh La Lemin Lemonades to be sold in Town Pump Convenience Stores in Montana
